Scandinavian ChemoTech remains positive to CE marking despite absent response before deadline

Due to the large number of accumulated applications that all control bodies experience, we do not know for sure if the result will come before 26 May. Despite the lack of a response to the Company's CE marking application, ChemoTech remains positive.

At present, all control bodies are struggling to process the final phase of all applications for CE markings under the current MDD regulations, which is a regulatory and strict process without shortcuts.

“We know that many shareholders are eagerly awaiting the statement on ChemoTech's CE marking of the IQwave™ and our TSE technology. Unfortunately, we do not know more than what we have already published in previous press releases, but we are still positive even if no response has been received before 26 May. " - says Mohan Frick, CEO of Scandinavian ChemoTech

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.